Verified source report
CVS Paying $36.5 Million for Overbilling Medi-Cal for Insulin Pens
CVS is paying $36.5 million for submitting false claims to the Medi-Cal program for excessive dispensing of insulin pens. A settlement pursued by California Attorney General Rob Bonta in collaboration with the United States Department of Justice with CVS Pharmacy, …
What happened
According to Insurance Journal’s source item, CVS Paying $36.5 Million for Overbilling Medi-Cal for Insulin Pens, CVS is paying $36.5 million for submitting false claims to the Medi-Cal program for excessive dispensing of insulin pens. A settlement pursued by California Attorney General Rob Bonta in collaboration with the United States Department of Justice with CVS Pharmacy, …
Context
The development sits in VINI’s Markets file for readers following markets, companies, finance, insurance, public policy, and economic signals. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-06-16T05:00:59+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: CVS Paying $36.5 Million for Overbilling Medi-Cal for Insulin Pens via Insurance Journal. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.
Source links
- CVS Paying $36.5 Million for Overbilling Medi-Cal for Insulin PensInsurance Journal - 2026-06-16T05:00:59+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.